SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " 2.3 billion " 12 found 🔀 AI-powered Shuffle
Ballot initiatives drive a flood of political mail
With six days to go until Election Day, the tally hasn’t been fully tolled, but it sure seems like we’re receiving more political mail this year than in previous campaigns. According to the Postal Regulatory Commission, an independent federal agency of the U.S. government, the country delivered more than 2.3 billion pieces of political mail […]
Uber to acquire ezCater for $2.3B, expanding catering reach
Uber plans a $2.3 billion acquisition of ezCater to expand into catering, offering large order delivery for business events.
Uber to buy US catering platform ezCater for $2.3 billion
Oct 6 (Reuters) - Uber said on Tuesday it would buy US catering platform ezCater in an all-cash deal for $2.3 billion, expanding its food delivery and workplace meals business.
Nvidia’s Israeli networking business is booming, and so is its economic footprint
The company’s networking revenue reached $32.3 billion in just the first half of fiscal 2027, already surpassing the previous full-year total. Much of the technology behind the business traces back to Mellanox and Nvidia’s Israeli development centers.
Fans, business owners react to Rays leaving St. Pete: 'A big change'
As the Tampa Bay Rays move closer to a $2.3 billion ballpark in Tampa, St. Pete businesses surrounding Tropicana Field are preparing for a new reality without the team.
AbCellera women’s health data top ‘most aggressive upside scenario,’ putting Astellas and Bayer on notice
AbCellera has reported phase 2 results “beyond even the most aggressive upside scenario” that its CEO dared to consider, boosting the biotech’s chances of challenging Astellas and Bayer for a women’s health market. The phase 2 clinical trial compared ABCL635, an antibody targeting NK3R, to placebo in patients with hot flashes caused by menopause. Investigators enrolled 92 postmenopausal women experiencing a mean of about 10 moderate or severe hot flashes per day. By Week 4, the number of moderate or severe hot flashes had fallen by a mean of 8.8 on ABCL635 and by 3.5 on placebo. That statistically significant, placebo-adjusted reduction of 5.3 hit the trial’s primary endpoint. The level of efficacy also cleared the bar set by existing drugs. While cross-trial comparisons can be misleading, AbCellera CEO Carl Hansen, Ph.D., had seen enough to start hyping the program. “We now view ABCL635 as a potential best-in-class non-hormonal therapy with strong differentiation against approved NK3R competitors across all important dimensions, including efficacy, safety, dosing and convenience,” Hansen said on a Monday morning conference call with investors to discuss the data. “We believe ABCL635 is now a highly de-risked program.” Last week, Hansen used AbCellera’s earnings call to set expectations for readout, with the CEO defining success as a clean safety profile and efficacy comparable to the two approved small molecules. The data vaulted over that bar. Astellas linked (PDF) one of the small molecules, Veozah, to placebo-adjusted reductions in hot flash frequency of 2.1 and 2.6 at Week 4 of its two phase 3 trials. Bayer reported (PDF) placebo-adjusted reductions of 3.04 and 3.29 at Week 4 of pivotal studies for its small molecule, Lynkuet. At 5.3, the placebo-adjusted reduction in AbCellera’s trial comfortably cleared the standard set by the incumbents. Veozah and Lynkuet came to market based on evidence of their ability to reduce the frequency and severity of hot flashes. AbCellera’s phase 2 study covered both endpoints, with the Canadian biotech reporting a mean reduction in severity of 1.4 points at Week 4 on ABCL635, compared to 0.3 points for placebo. Again, the placebo-adjusted result compares favorably to data on Veozah and Lynkuet. Analysts shared Hansen’s enthusiasm for the data. The phase 2 results “firmly validate ABCL635 as a potentially best-in-class treatment,” BMO Capital Markets analysts said in a note to investors Monday. ABCL635’s apparent efficacy edge “is likely attributable to the higher dosing/target engagement the asset is able to reach vs. the oral agents due to its wider therapeutic index,” the analysts added. The analysts, who model $2.3 billion in unadjusted peak sales for ABCL635, flagged the safety profile as another positive of the phase 2 readout. While Veozah carries a boxed warning for liver damage, nobody on ABCL635 in the phase 2 trial had elevated liver enzymes or bilirubin values. If replicated in phase 3, the lack of a liver signal could allow approval without the monitoring requirements imposed on Veozah. Investors appeared equally enthused, sending AbCellera's stock up 32% to $9.21 in premarket trading Monday from a Friday closing price of $6.93. Next, AbCellera will collect the Week 12 data and talk to its advisors about further development. The results open up “a wide variety of possibilities of how we might take this forward into phase 3 studies to truly maximize the value of the asset and make sure that ABCL635 is able to demonstrate its differentiation potential,” Sarah Noonberg, M.D., Ph.D., AbCellera’s chief medical officer, told investors.
Tyson cuts profit outlook as beef business struggles
The country’s largest meatpacker now sees annual adjusted operating income of $2.1 billion to $2.3 billion for fiscal year 2026, lowering its range by $100 million.
Mexican Billionaire Builds Next Banking Bet After Citi Deal
After reaching a $2.3 billion deal to buy a stake in Banamex, Fernando Chico Pardo plots out the path for the Mexican banking business.
Anglo American Writes Down De Beers Diamond Unit Value by Another $2.3 Billion
It is the third time in three years that Anglo American writes down the value of its diamond business.
Sony Pictures Entertainment Posts 12% Quarterly Revenue Decline
Sony Pictures Entertainment Feb. 4 reported a 12% third-quarter (ended Dec. 31, 2025) revenue decline to under $2.3 billion compared with revenue of more than $2.6 billion in the previous-year period. Operating income dropped more than 11% to $197 million from operating income of $223 million. The top-grossing movie in the current quarter included Chainsaw … Continue reading "Sony Pictures Entertainment Posts 12% Quarterly Revenue Decline"
Sphere Entertainment’s New Playbook: Smaller Venues, Less Risk, Bigger Returns
The $2.3 billion Las Vegas Sphere looked like a financial disaster at first glance, but a deeper look reveals why smaller venues may be the key to making the entire model work.
US signs health agreements with African nations, warns against nonperformance
The U.S. signed four new global health memorandums of understanding (MOUs) with Madagascar, Sierra Leone, Botswana, and Ethiopia, which total nearly $2.3 billion in funding, the State Department said on Tuesday.